United Therapeutics is pushing the limits of innovation with ground-breaking biomedical research. They address the national shortage of transplantable lungs and other organs with a variety of biotechnology tools that either delay the need for such organs or expand the supply. To facilitate their move from co-working space in Kendall Square to a re-purposed 19th-century mill-work building, they required a renovated laboratory and sophisticated workplace to attract and retain the best and brightest researchers.
Page's design includes a flexible layout for undefined future equipment and beta testing of new technological models. The facility is designed to Good Laboratory Practices (GLP) standards and easily accommodates upgrades as needed.
Building Facts
- Design-Bid-Build
- Renovation
- 16,000 SF
Transforming the Treatment of Rare Diseases
United Therapeutics is working to transform the lives of people living with pulmonary arterial hypertension (PAH), a rare disease causing high blood pressure in the lungs, by developing new medications and spearheading cure research. A core focus of their research is increasing the supply of transplantable lungs using ex vivo lung perfusion (EVLP) to minimize swelling in donor lungs thereby increasing the chance that they can be considered for transplant.